Jasper Therapeutics (JSPR) Income from Non-Controlling Interests (2020 - 2021)
Jasper Therapeutics (JSPR) posted quarterly Income from Non-Controlling Interests of -$3.6 million for Q2 2021, down 4.01% year-over-year from -$3.7 million in Q2 2020, and down 164.92% quarter-over-quarter from $5.5 million in Q1 2021.
Jasper Therapeutics (JSPR) Income from Non-Controlling Interests (2020 - 2021) Analysis & Trends
Jasper Therapeutics' Income from Non-Controlling Interests history runs 2 years deep, the most recent figure standing at -$3.6 million for Q2 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | Jasper Therapeutics | 20.08 Mn | 20.08 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | -3.57 Mn |
| Mar 31, 2021 | 5.50 Mn |
| Jun 30, 2020 | -3.43 Mn |
| Mar 31, 2020 | 1.21 Mn |